Médico advierte seis riesgos al suspender fármacos GLP-1

Médico advierte seis riesgos al suspender fármacos GLP-1

Salud
Inicia sesión para fijar este evento

El médico Frank Dumont, del Guy’s and St Thomas’ NHS Foundation Trust en Londres, advirtió que suspender los medicamentos GLP-1 para la pérdida de peso, como Ozempic, Wegovy o Zepbound, puede provocar seis riesgos para la salud, entre ellos el aumento de peso, la pérdida de masa muscular y el empeoramiento de los marcadores metabólicos. Indicó que estos efectos resaltan la necesidad de una gestión cuidadosa al interrumpir el tratamiento.

Un análisis observacional de más de 80 000 pacientes italianos con diabetes tipo 2, publicado en Lancet Regional Health y reportado por The Times, encontró que dejar la terapia GLP-1 se asoció con aproximadamente el doble de riesgo de infarto, ictus o muerte, sin depender de cambios en el peso o la glucosa. Según Global News, el riesgo fue particularmente elevado entre los pacientes con obesidad.

Actores

Guy's and St Thomas' NHS Foundation Trust Sonya Babu-Narayan British Heart Foundation Royal Brompton Hospital Faye Riley Diabetes UK

Ubicaciones

Italy London, England, United Kingdom

Verificación de hechos

Cómo funcionan estas métricas
Veredicto general: Parcialmente confirmado Confianza: 67% Afirmaciones: 4
Resumen

Four claims were partially confirmed: the increased risk after stopping GLP-1 therapy was notably higher in patients with obesity; physician Frank Dumont's warning about six health risks including weight regain, loss of muscle mass, and worsening metabolic markers upon discontinuation of GLP-1 weight-loss drugs; an observational study of over 80,000 Italian type-2 diabetes patients linking cessation of GLP-1 therapy to about twice the risk of heart attack, stroke, or death; and that the heightened risk of these cardiovascular events after stopping GLP-1 therapy occurred independently of weight or blood sugar changes. One claim stating that the health risks statement originated from Guy’s and St Thomas’ NHS Foundation Trust in London had insufficient evidence.

Inicia sesión o suscríbete para ver el análisis completo con afirmaciones, fuentes y validación cronológica.

Registrarse Iniciar sesión

Esta sección contiene una verificación automatizada de afirmaciones con fuentes externas y puede incluir imprecisiones.

Artículos

12 de noviembre de 2026
2 en total
6 surprising risks of quitting GLP-1 weight-loss drugs, according to experts
6 surprising risks of quitting GLP-1 weight-loss drugs, according to experts

Fox News • 12 de nov 13:00

Physician Frank Dumont outlines potential rebound effects—including hunger, weight regain, biomarker changes, muscle loss, mental-health impacts, and reduced cardiovascular protection—if patients stop GLP-1 medications without sustained lifestyle changes.

Credibilidad 72% Manip. 12% Centro
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns

Yahoo Health • 12 de nov 13:00

Physician Frank Dumont outlines potential rebound effects—including weight regain, loss of muscle, and worsening metabolic markers—when patients discontinue GLP-1 medications such as Ozempic, Wegovy or Zepbound.

Credibilidad 78% Manip. 12% Centro
11 de noviembre de 2026
1 en total
Stopping GLP-1 drugs could increase heart attack risk for some, study says
Stopping GLP-1 drugs could increase heart attack risk for some, study says

Global News • 11 de nov 19:59

An observational study of over 80,000 Italian patients found that discontinuing GLP-1 drugs was associated with roughly double the risk of heart attack, stroke or death, especially among those with obesity.

Credibilidad 88% Manip. 8% Centro
9 de noviembre de 2026
2 en total
Stopping fat jabs 'doubles the risk of heart attack, stroke or death', study warns
Stopping fat jabs 'doubles the risk of heart attack, stroke or death', study warns

The Sun • 9 de nov 23:30

An observational analysis of Italian diabetes clinic records found that patients with type 2 diabetes who stopped GLP-1 therapy faced roughly double the risk of heart attack, stroke or death compared with those who remained on the medication.

Credibilidad 82% Manip. 12% Centro
Stopping weight-loss jabs ‘increases heart attack risk for diabetics’
Stopping weight-loss jabs ‘increases heart attack risk for diabetics’

The Times • 9 de nov 23:30

Research of over 80,000 Italian patients suggests that stopping GLP-1 therapy may double the risk of heart attack, stroke or death among people with type 2 diabetes, independent of weight or blood-sugar changes.

Credibilidad 88% Manip. 8% Centro

Eventos relacionados